Mylan Nv Ord Shs (MYL) 39.97 $MYL Next Support Level for

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mylan Nv Ord Shs (MYL) 39.97 $MYL

Next Support Level for Mylan (MYL) is $40.95
Comtex SmarTrend(R) - Fri Sep 02, 9:10AM CDT
Shares of Mylan (NASDAQ:MYL) opened today below their pivot of $42.03 and have already reached the first level of support at $41.44. Should the shares continue to fall, the support pivots of $40.95 and $39.87 will be of interest.
MYL: 39.97 (-1.95)

Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)

Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar
Arpita Dutt - Zacks Investment Research - Fri Sep 02, 8:17AM CDT
Drug pricing is back in focus with lawmakers questioning Mylan's (MYL) pricing policy for EpiPen.
MRK: 62.98 (+0.08), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), BMY: 56.35 (-0.41), NVS: 79.38 (+1.11)

Generic Drugs Stocks Technical Reports -- Mylan, Horizon Pharma, Allergan, and Akorn
PR Newswire - Fri Sep 02, 6:40AM CDT
Rising costs of brand-name medicines continue to drive more and more consumers to settle for the much cheaper Generic Drugs. This morning, Stock-Callers.com presents four stocks within the Generic Drugs space for review, one of which has dominated the headlines just recently. Let us take a look at our featured companies: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Akorn Inc. (NASDAQ: AKRX). Download the free research reports on these stocks today: http://stock-callers.com/registration
AGN: 235.96 (-1.80), AKRX: 26.47 (-0.21), HZNP: 17.84 (-0.78), MYL: 39.97 (-1.95)


Clinton offers plan to prevent 'excessive' drug price hikes
By CATHERINE LUCEY - AP - Fri Sep 02, 6:08AM CDT
DES MOINES, Iowa (AP) — Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs.
MYL: 39.97 (-1.95)

Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding
PR Newswire - Thu Sep 01, 2:12PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S. Patent and Trademark Office (PTO) has ruled in favor of Mylan in its inter partes review (IPR) proceeding and found all claims of U.S. Patent No. 8,969,302, which is owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd., unpatentable. This is the third patent related to Copaxone® 40 mg/mL to be found unpatentable in the last week.
MYL: 39.97 (-1.95)

Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 76.89 (-0.53), ALXN: 123.67 (-1.96), MYL: 39.97 (-1.95), AMGN: 169.77 (-0.36), ARIA: 10.12 (-0.07), RIGL: 3.40 (-0.05), REGN: 388.64 (-4.76)

SmarTrend Watching for Potential Rebound in Shares of Mylan After 1.59% Loss
Comtex SmarTrend(R) - Wed Aug 31, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.02 to a high of $42.63. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.47 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 39.97 (-1.95)


20 Democratic senators blast steep price hike for EpiPens
By MATTHEW DALY - AP - Tue Aug 30, 4:51PM CDT
WASHINGTON (AP) — In a sign of growing concern in Congress, 20 Democratic senators are demanding answers about steep price hikes for the life-saving EpiPen injector device.
MYL: 39.97 (-1.95)

Company News for August 30, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:10AM CDT
Companies in the News are: MYL,HLF,CZR,CORE
HLF: 61.35 (+0.18), MYL: 39.97 (-1.95), CZR: 6.15 (-0.08), CORE: 38.61 (+0.81)

Business Highlights
By The Associated Press - AP - Mon Aug 29, 5:07PM CDT
WASHINGTON (AP) — ___
INO: 9.08 (-0.06), MDLZ: 44.19 (+0.24), HSY: 99.30 (-0.24), MYL: 39.97 (-1.95), UAL: 51.09 (+0.20)


Mylan launching cheaper, generic version of EpiPen
By LINDA A. JOHNSON and TOM MURPHY - AP - Mon Aug 29, 4:20PM CDT
The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues — and looming competition threatens its near-monopoly.
ESRX: 72.54 (+0.32), MYL: 39.97 (-1.95)

Your Complete Guide to the Generic Drug Industry
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 4:13PM CDT
Today we'll take a look at how generics are developed and how they affect the drug industry today.
AGN: 235.96 (-1.80), GNRX: 24.40 (-0.14), PRGO: 90.75 (-0.50), AXGN: 8.89 (-0.10), AKRX: 26.47 (-0.21), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), AMPH: 18.56 (-0.43), NVS: 79.38 (+1.11)

Mylan Promises $300 Generic EpiPen
Ryan McQueeney - Zacks Investment Research - Mon Aug 29, 12:04PM CDT
Pharmaceutical company Mylan NV (MYL) announced Monday that it will launch a generic version of the EpiPen at a 50% discount to the standard version of its popular allergy medication.
MYL: 39.97 (-1.95)

Watch for Shares of Mylan (MYL) to Approach Resistance at $44.56
Comtex SmarTrend(R) - Mon Aug 29, 8:34AM CDT
Mylan (NASDAQ:MYL) has opened bullishly above the pivot of $43.21 today and has reached the first level of resistance at $43.80. Analysts will be watching for a cross of the next upside pivot targets of $44.56 and $45.91.
MYL: 39.97 (-1.95)

The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 31.79 (-1.58), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), USNA: 138.16 (+1.81), TEVA: 51.22 (+0.32)

Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product
PR Newswire - Mon Aug 29, 5:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that its U.S. subsidiary will launch the first generic to EpiPen® Auto-Injector (epinephrine injection, USP) at a list price of $300 per generic EpiPen® two-pack carton, which represents a discount of more than 50% to the Mylan list price, or wholesale acquisition cost ("WAC" , of the branded medicine. The authorized generic will be identical to the branded product, including device functionality and drug formulation. Mylan expects to launch the product in several weeks, pending completion of labeling revisions. Upon launch, the product will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths. Mylan also intends to continue to market and distribute branded EpiPen®.
MYL: 39.97 (-1.95)

Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.79 (-1.58), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), USNA: 138.16 (+1.81)

Is the "Internet of Things" a Fad or the Future?
Madeleine Johnson - Zacks Investment Research - Fri Aug 26, 11:11AM CDT
On today's episode of the Zacks Friday Finish Line podcast, the hosts discussed Mylan's (MYL) epipen controversy, Amazon's (AMZN) rumored new music streaming service, and whether or not the "Internet of Things" is here to stay.
AMZN: 772.44 (+1.82), MYL: 39.97 (-1.95)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 84

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading